VLDLR Antikörper (AA 551-650) (Cy7)
Kurzübersicht für VLDLR Antikörper (AA 551-650) (Cy7) (ABIN705557)
Target
Alle VLDLR Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 551-650
-
Kreuzreaktivität
- Human, Maus
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human VLDL Receptor
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- FCM 1:20-100
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- VLDLR (Very Low Density Lipoprotein Receptor (VLDLR))
-
Andere Bezeichnung
- VLDL Receptor
-
Hintergrund
-
Synonyms: CARMQ1, CHRMQ1, VLDLRCH, Very low-density lipoprotein receptor, VLDL receptor, VLDL-R, VLDLR
Background: Binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binding to Reelin induces tyrosine phosphorylation of Dab1 and modulation of Tau phosphorylation (By similarity).
-
Gen-ID
- 7436
-
UniProt
- P98155
-
Pathways
- Cellular Response to Molecule of Bacterial Origin
Target
-